Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

BACKGROUND: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both bee...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Autores principales: Overman, M J, Adam, L, Raghav, K, Wang, J, Kee, B, Fogelman, D, Eng, C, Vilar, E, Shroff, R, Dasari, A, Wolff, R, Morris, J, Karunasena, E, Pisanic, R, Azad, N, Kopetz, S
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834085/
https://ncbi.nlm.nih.gov/pubmed/29069279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx688
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares